A Protein-Binding Molecular Photothermal Agent for Tumor Ablation

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Photothermal therapy (PTT) typically requires high power densities, causing damage to normal tissues.
• Existing photothermal agents often lead to inflammation and limited therapeutic efficacy due to heat loss and molecular leakage.

Purpose of the Study:

• To develop a novel molecular photothermal agent using a protein-binding strategy for enhanced tumor ablation.
• To investigate the efficacy of this agent under low power density conditions.
• To improve the therapeutic outcome of photothermal therapy by minimizing damage to normal tissues.

Main Methods:

• Synthesized a molecular photothermal agent designed to covalently bind to intracellular proteins via thiol groups.
• Utilized a low power density (0.2 W/cm²) for photothermal activation.
• Conducted in vitro and in vivo experiments to evaluate therapeutic effects and safety.

Main Results:

• The protein-binding strategy enabled effective destruction of bioactive proteins within cells.
• Low power density photothermal activation was sufficient to induce apoptosis.
• Demonstrated significantly improved therapeutic effects in both in vitro and in vivo models.
• Reduced heat loss and molecular leakage compared to conventional PTT.

Conclusions:

• The developed protein-binding strategy offers a promising approach for targeted tumor ablation.
• This method enhances photothermal therapy efficacy at low power densities, minimizing damage to surrounding healthy tissues.
• The molecular photothermal agent shows potential for improved cancer treatment outcomes.